DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,054 filers reported holding DANAHER CORPORATION in Q4 2021. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $62,705,123 | +7.8% | 252,741 | +4.3% | 0.07% | +12.5% |
| Q2 2023 | $58,163,118 | +1.4% | 242,346 | +6.5% | 0.06% | 0.0% |
| Q1 2023 | $57,368,671 | -9.5% | 227,617 | -4.7% | 0.06% | -12.3% |
| Q4 2022 | $63,381,852 | +8.8% | 238,798 | +5.9% | 0.07% | +7.4% |
| Q3 2022 | $58,259,000 | -6.2% | 225,556 | -7.9% | 0.07% | -4.2% |
| Q2 2022 | $62,085,000 | -9.9% | 244,889 | -10.7% | 0.07% | +2.9% |
| Q1 2022 | $68,874,000 | -25.1% | 274,231 | -1.9% | 0.07% | -18.8% |
| Q4 2021 | $92,001,000 | +1.1% | 279,631 | -6.5% | 0.08% | -4.5% |
| Q3 2021 | $91,030,000 | +12.7% | 299,010 | -0.6% | 0.09% | +14.1% |
| Q2 2021 | $80,766,000 | +10.7% | 300,962 | -7.2% | 0.08% | +4.0% |
| Q1 2021 | $72,984,000 | -15.3% | 324,257 | -16.4% | 0.08% | -21.9% |
| Q4 2020 | $86,193,000 | +18.6% | 388,013 | +15.0% | 0.10% | +3.2% |
| Q3 2020 | $72,655,000 | +16.0% | 337,412 | -4.8% | 0.09% | +9.4% |
| Q2 2020 | $62,643,000 | -17.8% | 354,253 | -35.7% | 0.08% | +32.8% |
| Q1 2020 | $76,208,000 | +29.4% | 550,596 | +43.5% | 0.06% | -11.1% |
| Q4 2019 | $58,905,000 | -5.3% | 383,797 | -10.8% | 0.07% | -10.0% |
| Q3 2019 | $62,173,000 | +940.7% | 430,471 | +929.9% | 0.08% | +566.7% |
| Q2 2019 | $5,974,000 | +18.8% | 41,797 | +9.7% | 0.01% | +9.1% |
| Q1 2019 | $5,030,000 | -14.2% | 38,100 | -33.0% | 0.01% | -26.7% |
| Q4 2018 | $5,861,000 | -5.5% | 56,839 | -0.4% | 0.02% | +15.4% |
| Q3 2018 | $6,202,000 | +20.7% | 57,073 | +9.6% | 0.01% | +18.2% |
| Q2 2018 | $5,140,000 | +11.0% | 52,086 | +10.2% | 0.01% | +10.0% |
| Q1 2018 | $4,629,000 | +8.4% | 47,279 | +2.8% | 0.01% | +11.1% |
| Q4 2017 | $4,270,000 | +17.6% | 46,008 | +8.7% | 0.01% | +12.5% |
| Q3 2017 | $3,630,000 | -77.7% | 42,318 | -78.1% | 0.01% | -78.9% |
| Q2 2017 | $16,288,000 | -22.0% | 193,016 | -20.9% | 0.04% | -24.0% |
| Q1 2017 | $20,880,000 | -10.6% | 244,123 | -18.6% | 0.05% | -15.3% |
| Q4 2016 | $23,344,000 | -14.1% | 299,892 | -13.5% | 0.06% | -22.4% |
| Q3 2016 | $27,168,000 | -24.6% | 346,577 | -2.8% | 0.08% | -47.2% |
| Q2 2016 | $36,011,000 | -3.5% | 356,554 | -9.4% | 0.14% | -6.5% |
| Q1 2016 | $37,324,000 | -21.3% | 393,465 | -23.0% | 0.15% | -21.8% |
| Q4 2015 | $47,438,000 | -5.3% | 510,749 | -13.1% | 0.20% | -4.4% |
| Q3 2015 | $50,087,000 | -10.4% | 587,796 | -10.0% | 0.21% | -0.5% |
| Q2 2015 | $55,890,000 | -22.9% | 652,934 | -23.5% | 0.21% | -20.4% |
| Q1 2015 | $72,444,000 | -12.9% | 853,286 | -12.0% | 0.26% | -15.0% |
| Q4 2014 | $83,150,000 | -29.9% | 970,141 | -37.9% | 0.31% | -65.8% |
| Q3 2014 | $118,686,000 | -8.9% | 1,562,050 | -5.8% | 0.90% | +1.4% |
| Q2 2014 | $130,268,000 | +66.1% | 1,658,214 | +58.6% | 0.88% | +66.0% |
| Q1 2014 | $78,433,000 | +31.4% | 1,045,761 | +35.2% | 0.53% | +26.4% |
| Q4 2013 | $59,690,000 | -26.0% | 773,428 | -33.5% | 0.42% | -27.3% |
| Q3 2013 | $80,639,000 | – | 1,163,294 | – | 0.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |